Skip to main content
OpenTrials
Completed

NCT Number: NCT05105776

Multimodal Neuromodulation in Individuals With Parkinson's Disease

Multimodal non-invasive neuromodulation paired with physical therapy is a promising treatment modality for Parkinson's Disease ("PD"), however the optimal stimulation method, dose, and associated therapeutic protocol for long-lasting clinical benefits have not yet been identified for this population.

Here the investigators aim to develop and execute a preliminary clinical study exploring the potential benefits of multimodal non-invasive neuromodulation. The therapeutic intervention will involve translingual neurostimulation +/- galvanic neurostimulation, paired with an intensive physical and cognitive therapy program.

Completed

Looking for future studies?

Notify Me

Key information

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Centre for Neurology Studies

Surrey, British Columbia, V3V 0C6, Canada

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • A diagnosis of idiopathic PD
  • Disease staging between II and III (mild to moderate), according to the modified Hoehn and Yahr scale;
  • Currently taking prescribed antiparkinsonian medication regularly with:
  • No medication changes in the last 30 days
  • Responsive to oral dopamine replacement therapy
  • Score higher than 24, verified through the Montreal Cognitive Assessment33.
  • Must demonstrate moderate burden of motor symptoms (MDS-UPDRS part II >12 and MDS-UPDRS part III scores >35) 34
  • Must be able to voluntarily give written (or verbal) informed consent
  • Must have ability to reliably use the devices
  • Must be able to understand and complete all assessments (provided in English only)

Exclusion criteria

  • Diagnosis of atypical parkinsonism;
  • History of epilepsy
  • Presence of an implanted electrical device
  • Previous surgical intervention for PD (DBS implantation - deep brain stimulation);
  • Treated with a pump for continuous delivery of DRT (Dopamine replacement therapy)
  • Presence of severe freezing episodes.
  • Women who are pregnant or nursing
  • History of unstable mood disorder or unstable anxiety disorder or psychosis
  • Those with a recent history of substance abuse and/or dependence (alcohol or other drugs)
  • Have been diagnosed with neurological disease other than Parkinson's disease.
  • Have a major concomitant illness or illnesses including cancer or disease of the cardiovascular, respiratory and/or renal systems deemed significant medical risk in the opinion of the principle investigator
  • Have a diagnosed vestibular dysfunction
  • Have had eye surgery within the previous three months or ear surgery within the previous six months
  • Have participated in another clinical trial within the last 30 days or are currently enrolled in another interventional clinical trial
  • Contraindicated for PoNS, including:

25.1. Current disease or sensitivity of the oral cavity 25.2. History of oral cancer 25.3. Oral surgery within three months of screening 25.4. Oral cavity piercings that could interfere with PoNSTM use 25.5. Sensitivity to Nickel, Copper, or Gold 25.6. Currently enrolled in a PoNSTM treatment program or use of the PoNSTM device in the last 5 weeks 25.7. History of penetrating brain injuries 25.8. Chronic infectious disease 25.9. Unmanaged hypertension 25.10. Diabetes 25.11. History of seizures

  • Contraindicated for GVS, including:

26.1. Metallic brain implant(s) 26.2. Brain surgery within the past six months 26.3. Highly sensitive skin behind the ears

Treatment and study plan

Galvanic stimulation

Device

Galvanic stimulation during physiotherapy sessions

Primary outcomes

  1. NeuroCom Sensory Organization Test (SOT)

    Time frame: Baseline to week 4

    Composite balance score

  2. NeuroCom Limits of Stability test (LOS)

    Time frame: Baseline to week 4

    Postural stability score

  3. NeuroCom Adaptation Test

    Time frame: Baseline to week 4

    Adaptation score

  4. MiniBESTest

    Time frame: Baseline to week 4

    Balance score

Secondary outcomes

  1. Electroencephalography - amplitudes

    Time frame: Baseline to week 4

    Measured with NeuroCatch Platform 2 (NCP)

  2. Electroencephalography - latencies

    Time frame: Baseline to week 4

    Measured with NeuroCatch Platform 2 (NCP)

  3. Unified Parkinson's Disease Rating Scale

    Time frame: Baseline to week 4

    Part II and part III: Motor function score

  4. Montreal Cognitive Assessment (MoCA)

    Time frame: Baseline to week 4

    Cognitive test; total score

Sponsors and collaborators

Lead sponsor

Ryan D'Arcy

Industry

Collaborators

  • Pacific Parkinson's Research Institute
  • University of British Columbia

Registry information

Important dates

Study start
2022
Primary completion
2024
Study completion
2024
First posted
Nov 3, 2021
Registry last updated
May 29, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.